The COVID-19 is one of the most important recent events in the world. Its long asymptomatic incubation period, efficient airborne transmission and high infectivity have contributed to its rapid global spread. The spectrum of symptoms, mortality and morbidity varies widely. Chronic diseases are an important risk factor for the development of severe and fatal forms of COVID-19. Many studies have confirmed that malignant hematological diseases have the worst morbidity and mortality outcomes. Currently, the most effective way to fight infection is through vaccination. This has been effective and has had a dramatic effect on reducing serious illness and mortality rates in the general population, but the benefits of the vaccine have not been successfully replicated in patients with hematological malignancies. The COVID-19 pandemic poses several medical challenges that encourage researchers and clinicians to provide the best possible care for patients with hematological malignancies during this difficult period.